Continued macroeconomic uncertainty has far reaching implications for the biopharma ecosystem. Access to capital remains low across the industry, and a successful deal with large pharma has become less likely for many...

Rising awareness and emergence of differentiated solutions for multiple psychiatric and mental health conditions is an ongoing theme of innovation in pharma but also adjacent and “convergence” fields in healthcare. Increasing incidence, certainly exacerbated by lockdowns and other measures implemented to curtail the spread of COVID-19, and the significant lack of innovation in the past represent the key ingredients for a resurgence, which is currently emerging.

Capital allocation towards innovative health-tech solutions has fuelled an increase in adoption of digital technologies. We outline a few current themes and future trends in the area.